Alpha 2.0
Login Register
» Authors » Yoann Marechal

Yoann Marechal

Explore the profile of Yoann Marechal including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 148
Followers 0
Related Specialties
Biochemistry
Gynecology & Obstetrics
Pediatrics
Top 10 Co-Authors
Stephane Schurmans
Katleen Plaskie
Valerie Pouillon
Anton H van Kaam
Martin Offringa
Henry Blom
Wes Onland
Anne Debeer
Els Bruneel
Thilo Mohns
Published In
Arch Dis Child Fetal Neonatal Ed
Nucleic Acids Res
Immunobiology
JAMA
Intensive Crit Care Nurs
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessment of the Impact of Technical Incidents in Critical Situations Using High-Fidelity Simulation Techniques in Pediatric Intensive Care
Biot C, Sanoussi I, Marechal Y
Cureus . 2024 Jul; 16(7):e64381. PMID: 39007021
Introduction In certain fields such as anesthesia and critical care, technical incidents are rare events; however, when they occur, they disrupt workflow, optimal patient care, and survival, with human factors...
2.
Mass spectrometry analysis of environmental pollutants in breast and artificial milk for newborns
Goutelle A, Viseur J, Boudjeltia K, Nuyens V, Cavatorta E, Van Antwerpen P, et al.
Heliyon . 2024 Jul; 10(11):e32350. PMID: 38947466
Environmental toxins, particularly liposoluble compounds that accumulate in adipose tissues, present a risk for newborns, not only through breastfeeding but also through artificial milks. These compounds pass into breast milk,...
3.
Comparison of communication interfaces for mechanically ventilated patients in intensive care
Szymkowicz E, Bodet-Contentin L, Marechal Y, Ehrmann S
Intensive Crit Care Nurs . 2023 Oct; 80:103562. PMID: 37871352
Objectives: This study aimed to compare the use of a conventional low-tech communication board and a high-tech eye tracking device to improve communication effectiveness of mechanically ventilated patients in intensive...
4.
Identifying effect modifiers of systemic hydrocortisone treatment initiated 7-14 days after birth in ventilated very preterm infants on long-term outcome: secondary analysis of a randomised controlled trial
Halbmeijer N, Sonnaert M, Swarte R, Koopman-Esseboom C, van Stuijvenberg M, Mulder-de Tollenaer S, et al.
Arch Dis Child Fetal Neonatal Ed . 2023 Sep; 109(2):159-165. PMID: 37722765
Objective: To explore clinical effect modifiers of systemic hydrocortisone in ventilated very preterm infants for survival and neurodevelopmental outcome at 2 years' corrected age (CA). Design: Secondary analysis of a...
5.
Effect of systemic hydrocortisone in ventilated preterm infants on parent-reported behavioural outcomes at 2 years' corrected age: follow-up of a randomised clinical trial
Halbmeijer N, Onland W, Cools F, Swarte R, van der Heide-Jalving M, Dijk P, et al.
Arch Dis Child Fetal Neonatal Ed . 2023 Jan; 108(4):373-379. PMID: 36593110
Objective: To report the parent-reported behavioural outcomes of infants included in the Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants study at 2 years' corrected age (CA). Design: Randomised...
6.
Pilot Study to Evaluate a New Method for Endotracheal Administration of Surfactant in Neonatal Respiratory Distress Syndrome: Fiberscope Assisted Surfactant Therapy (FAST)
Guevorkian D, Cavatorta E, Rassart A, Vanden Eijnden S, Vicari A, Sanoussi I, et al.
Neonatology . 2022 Aug; 119(6):753-759. PMID: 36030773
Introduction: Currently, INSURE (Intubation-Surfactant-Extubation) and LISA (Less Invasive Surfactant Administration) are two recommended techniques for surfactant delivery to newborns with respiratory distress syndrome. The aim of this study was to...
7.
Short-term pulmonary and systemic effects of hydrocortisone initiated 7-14 days after birth in ventilated very preterm infants: a secondary analysis of a randomised controlled trial
Halbmeijer N, Onland W, Cools F, Kroon A, van der Heide-Jalving M, Dijk P, et al.
Arch Dis Child Fetal Neonatal Ed . 2022 May; 108(1):20-25. PMID: 35534184
Objective: Observational studies in preterm infants suggest that systemic hydrocortisone improves pulmonary condition but may also lead to systemic adverse effects. We report the short-term pulmonary and systemic effects of...
8.
Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial
Onland W, Cools F, Kroon A, Rademaker K, Merkus M, Dijk P, et al.
JAMA . 2019 Jan; 321(4):354-363. PMID: 30694322
Importance: Dexamethasone initiated after the first week of life reduces the rate of death or bronchopulmonary dysplasia (BPD) but may cause long-term adverse effects in very preterm infants. Hydrocortisone is...
9.
Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells
Pouillon V, Marechal Y, Frippiat C, Erneux C, Schurmans S
Adv Biol Regul . 2012 Sep; 53(1):39-50. PMID: 22981169
Mice genetically-deficient for the B isoform of the inositol 1,4,5-trisphosphate 3-kinase (or Itpkb) have a severe defect in thymocytes differentiation and thus lack peripheral T cells. In order to study...
10.
Regulation of B cell survival, development and function by inositol 1,4,5-trisphosphate 3-kinase B (Itpkb)
Schurmans S, Pouillon V, Marechal Y
Adv Enzyme Regul . 2010 Nov; 51(1):66-73. PMID: 21035494
In mammals, Ins(1,4,5)P3, the well known calcium mobilization messenger, is phosphorylated in the cytosol at the 3-position of the inositol ring to yield Ins(1,3,4,5)P4 by Ins(1,4,5)P3 3-kinases A, B and...